Other dual GLP1/GCCR agonists intended for use in NAFLD include pemvidutide (ALT-801) (NCT05006885), danuglipron (PF-06882961) (in combination with ervogastat) [129], BI 456906 (NCT04771273), and HM14320 (a glucagon-containing combination) [130]. Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.